Form 4: ADMA Biologics CEO Adam Grossman Reports Stock Transaction
SEC Form 4 Filing
Adam Grossman, CEO of ADMA Biologics, reports the disposition of 9,588 shares of common stock to cover tax obligations upon vesting of Restricted Stock Units (RSUs).
Summary
- On February 29, 2024, Adam Grossman, the President and CEO of ADMA Biologics, disposed of 9,588 shares of common stock at a price of $5.36 per share.
- This transaction was reported on a Form 4 filing with the SEC.
- The disposition was related to the withholding of shares to cover applicable taxes upon the vesting of previously granted RSUs.
- Following the transaction, Grossman directly owns 2,756,993 shares of ADMA Biologics common stock.
- Grossman also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for company insiders reporting transactions in their company's stock. This filing indicates routine tax-related stock disposals following RSU vesting, a common form of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 02/25/2021 | Date of grant for 45,785 unvested RSUs. |
| 09/29/2021 | Date of grant for 226,875 unvested Time-Based RSUs. |
| 03/07/2022 | Date of grant for 225,000 unvested RSUs. |
| 12/31/2022 | Time-Based RSUs granted on September 29, 2021, will vest in eight equal quarterly installments over a period of two years following this date. |
| 03/06/2023 | Date of grant for 573,695 RSUs. |
| 02/26/2024 | Date of grant for 557,728 RSUs. |
| 02/29/2024 | Date of stock transaction (disposal of 9,588 shares). |
| 03/04/2024 | Date of signature on the Form 4 filing. |
| 12/31/2024 | Time-Based RSUs granted on September 29, 2021, becoming fully vested on this date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.